Faes Farma, S.A.
https://faesfarma.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Faes Farma, S.A.
Pear Bankruptcy Filing Highlights Difficult Challenges Facing Digital Therapeutics
Pear Therapeutics filed for Chapter 11 bankruptcy in April and sold its remaining assets in an auction for about $6m. The demise of one the pioneers in the prescription digital therapeutics industry highlights the challenges PDT developers face getting their products reimbursed.
Opportunities Amid Crisis: Junshi, Allist Look To Expand Pipelines Through Alliances, M&A
Against the prevailing headwinds in the biotech sector, two Chinese firms are bucking the trend of pipeline reorganization by eyeing the potential acquisition of assets from external partners to expand into more modalities and therapeutic areas.
Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Idorsia Requests DEA Lift Controlled Substance Restrictions On Dual Orexin Receptor Antagonists For Insomnia
Schedule IV classification for Idorsia’s Quviviq, along with Merck & Co’s Belsomra and Eisai’s Dayvigo, distorts the drug class’ benefit-risk profile relative to other insomnia treatments, which are prioritized for prescribing but carry higher risk of abuse and other adverse events, company says.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice